Euregen Biopharma Co. Ltd. has disclosed son of sevenless homolog 1 (SOS1)/GTPase KRAS (G12C mutant) interaction inhibitors reported to be useful for the treatment of cancer.
Amygdala Neurosciences Inc. has described aldehyde dehydrogenase-2 (ALDH2) inhibitors reported to be useful for the treatment of anxiety disorder, binge eating disorder, alcoholism, and amphetamine, cocaine, nicotine and opioid dependence.
C4 Therapeutics Inc. has divulged proteolysis targeting chimeric (PROTAC) compounds comprising a protein cereblon (CRBN) binding moiety covalently bound to a probable global transcription activator SNF2L2 (SMARCA2; BAF190B; SNF2-α)-targeting moiety through a linker.
Neuron23 Inc. has identified non-receptor tyrosine-protein kinase TYK2 (JH2 domain) inhibitors reported to be useful for the treatment of neurological disorders.
Beijing Danatlas Pharmaceutical Technology Co. Ltd. has described heterocyclic derivatives acting as DNA polymerase θ (POLθ, POLQ) inhibitors reported to be useful for the treatment of cancer.
Researchers at Myrobalan Therapeutics Inc. and Myrobalan Therapeutics Nanjing Co. Ltd. have divulged macrophage colony-stimulating factor 1 receptor (CSF-1R; CD115; c-Fms) inhibitors reported to be useful for the treatment of cancer, autoimmune diseases, neurodegeneration, obesity, metabolic diseases, and inflammatory disorders.
Trawsfynydd Therapeutics Inc. has identified 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
RSS